HMGCR and diabetes mellitus: Major randomized clinical trials and meta-analyses of these trials have indicated that statin therapy, which inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, is associated with a modestly higher risk of developing type 2 diabetes mellitus in a dose-dependent fashion [41,42].